O	0	5	Proto	Proto	AFX	B-NP
O	5	6	-	-	HYPH	I-NP
O	6	14	oncogene	oncogene	NN	B-NP
O	15	16	N	N	NN	I-NP
O	16	17	-	-	HYPH	B-NP
O	17	20	myc	myc	NN	I-NP
O	21	29	promoter	promoter	NN	I-NP
O	30	32	is	be	VBZ	B-VP
O	33	37	down	down	RB	I-VP
O	38	47	regulated	regulate	VBN	I-VP
O	48	50	by	by	IN	B-PP
O	51	54	the	the	DT	B-NP
B-Cancer	55	60	Wilms	Wilms	NNP	I-NP
I-Cancer	60	61	'	'	POS	B-NP
I-Cancer	62	67	tumor	tumor	NN	I-NP
O	68	78	suppressor	suppressor	NN	I-NP
O	79	83	gene	gene	NN	I-NP
O	84	87	WT1	WT1	NN	I-NP
O	87	88	.	.	.	O

O	90	93	The	The	DT	B-NP
O	94	99	Wilms	Wilms	NNP	I-NP
O	99	100	'	'	POS	B-NP
O	101	106	tumor	tumor	NN	I-NP
O	107	108	1	1	CD	I-NP
O	109	110	(	(	(	O
O	110	113	WT1	WT1	NN	B-NP
O	113	114	)	)	)	O
O	115	119	gene	gene	NN	B-NP
O	120	122	is	be	VBZ	B-VP
O	123	124	a	a	DT	B-NP
B-Cancer	125	130	tumor	tumor	NN	I-NP
O	131	141	suppressor	suppressor	NN	I-NP
O	142	146	gene	gene	NN	I-NP
O	147	151	that	that	WDT	B-NP
O	152	159	encodes	encode	VBZ	B-VP
O	160	161	a	a	DT	B-NP
O	162	166	zinc	zinc	NN	I-NP
O	166	167	-	-	HYPH	B-NP
O	167	173	finger	finger	NN	I-NP
O	174	187	transcription	transcription	NN	I-NP
O	188	194	factor	factor	NN	I-NP
O	194	195	.	.	.	O

O	196	199	WT1	WT1	NN	B-NP
O	200	209	represses	repress	VBZ	B-VP
O	210	223	transcription	transcription	NN	B-NP
O	224	226	of	of	IN	B-PP
O	227	234	several	several	JJ	B-NP
O	235	241	growth	growth	NN	I-NP
O	242	249	factors	factor	NNS	I-NP
O	250	253	and	and	CC	O
O	254	260	growth	growth	NN	B-NP
O	261	267	factor	factor	NN	I-NP
O	268	277	receptors	receptor	NNS	I-NP
O	277	278	.	.	.	O

O	279	282	The	The	DT	B-NP
O	283	284	N	N	NN	I-NP
O	284	285	-	-	HYPH	I-NP
O	285	288	myc	myc	NN	I-NP
O	289	294	proto	proto	AFX	O
O	294	295	-	-	HYPH	O
O	295	303	oncogene	oncogene	NN	B-NP
O	304	311	encodes	encode	VBZ	B-VP
O	312	313	a	a	DT	B-NP
O	314	327	transcription	transcription	NN	I-NP
O	328	334	factor	factor	NN	I-NP
O	335	340	which	which	WDT	B-NP
O	341	350	regulates	regulate	VBZ	B-VP
B-Cell	351	355	cell	cell	NN	B-NP
O	356	362	growth	growth	NN	I-NP
O	363	366	and	and	CC	O
O	367	382	differentiation	differentiation	NN	B-NP
O	382	383	.	.	.	O

O	384	385	N	N	NN	B-NP
O	385	386	-	-	HYPH	I-NP
O	386	389	myc	myc	NN	I-NP
O	390	392	is	be	VBZ	B-VP
O	393	404	coexpressed	coexpresse	VBN	I-VP
O	405	409	with	with	IN	B-PP
O	410	413	WT1	WT1	NN	B-NP
O	414	416	in	in	IN	B-PP
O	417	420	the	the	DT	B-NP
O	421	431	developing	develop	VBG	I-NP
B-Organ	432	438	kidney	kidney	NN	I-NP
O	439	442	and	and	CC	O
O	443	445	is	be	VBZ	B-VP
O	446	459	overexpressed	overexpresse	VBN	I-VP
O	460	462	in	in	IN	B-PP
O	463	467	many	many	JJ	B-NP
B-Cancer	468	473	Wilms	Wilms	NNP	I-NP
I-Cancer	473	474	'	'	POS	B-NP
I-Cancer	475	481	tumors	tumor	NNS	I-NP
O	481	482	.	.	.	O

O	483	487	Here	Here	RB	B-ADVP
O	487	488	,	,	,	O
O	489	491	we	we	PRP	B-NP
O	492	496	show	show	VBP	B-VP
O	497	501	that	that	IN	B-SBAR
O	502	505	the	the	DT	B-NP
O	506	511	proto	proto	AFX	I-NP
O	511	512	-	-	HYPH	I-NP
O	512	520	oncogene	oncogene	NN	I-NP
O	521	522	N	N	NN	I-NP
O	522	523	-	-	HYPH	B-NP
O	523	526	myc	myc	NN	I-NP
O	527	535	promoter	promoter	NN	I-NP
O	536	539	was	be	VBD	B-VP
O	540	544	down	down	RB	B-ADVP
O	544	545	-	-	HYPH	B-NP
O	545	554	regulated	regulate	VBN	B-VP
O	555	557	by	by	IN	B-PP
O	558	561	WT1	WT1	NN	B-NP
O	562	564	in	in	IN	B-PP
O	565	574	transient	transient	JJ	B-NP
O	575	587	transfection	transfection	NN	I-NP
O	588	594	assays	assay	NNS	I-NP
O	594	595	.	.	.	O

O	596	603	However	However	RB	B-ADVP
O	603	604	,	,	,	O
O	605	611	mutant	mutant	JJ	B-NP
O	612	615	WT1	WT1	NN	I-NP
O	616	617	(	(	(	O
O	617	622	R394W	R394W	NN	B-NP
O	622	623	)	)	)	O
O	624	629	which	which	WDT	B-NP
O	630	633	has	have	VBZ	B-VP
O	634	635	a	a	DT	B-NP
O	636	644	mutation	mutation	NN	I-NP
O	645	647	in	in	IN	B-PP
O	648	651	the	the	DT	B-NP
O	652	655	DNA	DNA	NN	I-NP
O	656	663	binding	binding	NN	I-NP
O	664	670	domain	domain	NN	I-NP
O	671	676	could	could	MD	B-VP
O	677	680	not	not	RB	I-VP
O	681	688	repress	repress	VB	I-VP
O	689	692	the	the	DT	B-NP
O	693	694	N	N	NN	I-NP
O	694	695	-	-	HYPH	I-NP
O	695	698	myc	myc	NN	I-NP
O	699	707	promoter	promoter	NN	I-NP
O	707	708	.	.	.	O

O	709	724	Electrophoretic	Electrophoretic	JJ	B-NP
O	725	733	mobility	mobility	NN	I-NP
O	734	739	shift	shift	NN	I-NP
O	740	746	assays	assay	NNS	I-NP
O	747	753	showed	show	VBD	B-VP
O	754	758	that	that	IN	B-SBAR
O	759	762	the	the	DT	B-NP
O	763	779	oligonucleotides	oligonucleotide	NNS	I-NP
O	780	790	containing	contain	VBG	B-VP
O	791	794	the	the	DT	B-NP
O	795	798	WT1	WT1	NN	I-NP
O	799	805	motifs	motif	NNS	I-NP
O	806	811	could	could	MD	B-VP
O	812	816	bind	bind	VB	I-VP
O	817	828	recombinant	recombinant	JJ	B-NP
O	829	832	WT1	WT1	NN	I-NP
O	833	841	proteins	protein	NNS	I-NP
O	841	842	.	.	.	O

O	843	847	This	This	DT	B-NP
O	848	856	suggests	suggest	VBZ	B-VP
O	857	861	that	that	IN	B-SBAR
O	862	865	the	the	DT	B-NP
O	866	876	repression	repression	NN	I-NP
O	877	879	of	of	IN	B-PP
O	880	883	the	the	DT	B-NP
O	884	885	N	N	NN	I-NP
O	885	886	-	-	HYPH	I-NP
O	886	889	myc	myc	NN	I-NP
O	890	898	promoter	promoter	NN	I-NP
O	899	901	is	be	VBZ	B-VP
O	902	910	mediated	mediate	VBN	I-VP
O	911	918	through	through	IN	B-PP
O	919	922	the	the	DT	B-NP
O	923	926	WT1	WT1	NN	I-NP
O	927	934	binding	binding	NN	I-NP
O	935	940	sites	site	NNS	I-NP
O	940	941	.	.	.	O

O	942	946	This	This	DT	B-NP
O	947	954	finding	finding	NN	I-NP
O	955	958	may	may	MD	B-VP
O	959	963	help	help	VB	I-VP
O	964	966	to	to	TO	I-VP
O	967	976	elucidate	elucidate	VB	I-VP
O	977	980	the	the	DT	B-NP
O	981	993	relationship	relationship	NN	I-NP
O	994	996	of	of	IN	B-PP
O	997	1000	WT1	WT1	NN	B-NP
O	1001	1004	and	and	CC	I-NP
O	1005	1006	N	N	NN	I-NP
O	1006	1007	-	-	HYPH	B-NP
O	1007	1010	myc	myc	NN	I-NP
O	1011	1013	in	in	IN	B-PP
O	1014	1027	tumorigenesis	tumorigenesis	NN	B-NP
O	1028	1031	and	and	CC	O
B-Organ	1032	1037	renal	renal	JJ	B-NP
O	1038	1049	development	development	NN	I-NP
O	1049	1050	.	.	.	O

